The present invention relates to bioresorbable thermoset polyester/urethane elastomers and methods of making and using the same.
Bioresorbable elastomers are synthetic polymers that are broken down in vivo and can be used, for example, as coatings for stents and catheters, as drug delivery systems, as vascular grafts, as scaffolds for tissue engineering, and as guides for nerve growth. Examples of medical devices coated with such polymers are disclosed in U.S. patent application Ser. No. 12/783,261, the entire content of which is disclosed herein by reference. To achieve their widest utility, elastomers should be able to mimic the resilience, flexibility, and tensile strength exhibited by natural materials and encountered in a wide range of potential medical applications. However, bioresorbable elastomers currently known in the art have not simultaneously achieved high tensile strength, flexibility and low permanent deformation under cyclic mechanical use that approach what is found in nature. Accordingly, there is a need for a bioresorbable elastomer that combines high tensile strength with a high degree of flexibility and low permanent deformation.
The present invention addresses the need described above by providing bioresorbable elastomers and methods of making the same. The bioresorbable elastomers of the present invention have a range of applications, including but not limited to vascular grafts, drug delivery systems, stent coatings to improve radial recovery, and as tissue engineering substrates including nerve guides, small blood vessels, bladders, cardiac tissues, cartilages, tendons, and ligaments.
In one aspect, the present invention relates to bioresorbable elastomers that include a branched prepolymer and an isocyanate crosslinker and that have high tensile strength and a high degree of flexibility along with low permanent deformation under cyclic mechanical use.
In another aspect, the present invention relates to a method of making such a bioresorbable elastomer by providing a branched prepolymer and crosslinking it with an isocyanate crosslinker.
In still another aspect, the present invention relates to a method of optimizing the mechanical characteristics of a bioresorbable elastomer by optimizing the crosslink density and/or the average molecular weight of branched subunits. In certain embodiments, the tensile strength, flexibility, and long-term deformation of a bioresorbable elastomer are optimized by providing a symmetrical isocyanate crosslinker having a plurality of isocyanate moieties of equal reactivity during the curing of the bioresorbable elastomer. In other embodiments, these characteristics are optimized by adjusting the average molecular weight of the prepolymer used during production of the bioresorbable elastomer. In yet other embodiments, these characteristics are optimized by adjusting the ratio of prepolymer to cross-linker during production of the bioresorbable elastomer.
Bioresorbable thermoset elastomers (hereinafter, “elastomers”) of the present invention simultaneously exhibit high elongation at break, low permanent deformation, and high tear resistance; by contrast, other bioresorbable elastomers currently known in the art do not simultaneously exhibit all of these characteristics. Elastomers of the present invention achieve this balance of properties by tuning the balance between chemical crosslinking via covalent bonding with physical crosslinking via non-covalent interactions. Elastomers of the invention comprise “soft” segments including branched polyesters, and “hard” segments including urethane or urea, as depicted in
Elastomers of the present invention exhibit good strength, high elasticity and a high degree of elastic recovery under cyclic mechanical strain. These properties are due to the optimized crosslinked nature—the degree of crosslinking—of these branched prepolymers crosslinked with isocyanates in combination with the phase separation of the “soft” (polyester) and “hard” (urethane/urea) segments. The soft segments of the elastomer permit elongation of the material while the hard segments impart strength. The combination of the hard and soft segments impart elasticity. The tensile strength and elongation to break of these elastomers can be adjusted by varying the crosslink density. If the crosslink density is high the resultant elastomer is strong with low permanent deformation but has a low elongation to break. Alternatively if the crosslink density is too low the elastomer has a high elongation to break but is weak, tacky and has high permanent deformation. Additional strength may also be obtained from secondary bonds that form between adjacent polymer chains; these are primarily hydrogen bonds between the hard (urethane/urea) segments of these elastomers. Phase separation of the hard and soft segments will also add to the high elasticity and low permanent deformation associated with these elastomers.
Elasticity and tensile strength of the elastomers can be optimized by adjusting the molecular weight and structure of the prepolymer, the structure of the isocyanate crosslinker, and the ratio of prepolymer to crosslinker used in the curing process. In a preferred embodiment, the average molecular weight (Mn) of the 4-arm prepolymer is at least 20,000 g/mol (i.e., 20 kDa), and more preferably at least 30,000 g/mol (i.e., 30 kDa). At the beginning of the curing process, the isocyanate cross-linker can be provided in a ratio of between 5 to 1 and 120 to 1 (mol/mol) relative to the prepolymer.
In certain preferred embodiments, the prepolymer is a 4 arm polymer such as poly (glycolide-co-ε-caprolactone) (50:50) (PGCL) or poly (lactide-co-ε-caprolactone) (50:50) (PLCL). Other multi-arm polymers, such as the block or random copolymers of glycolide and/or lactide with poly(ε-caprolactone), poly(butylene succinate) (PBS), poly(p-dioxanone) (PDO), and Poly(trimethylene carbonate) (PTMC), may also be used as the prepolymers. The ratio of the individual monomers is not limited to 50:50 and any other ratios are valid unless the glass transition temperature of the resultant copolymers is above room temperature.
The crosslinker used in the present invention is any suitable symmetrical isocyanate. In certain preferred embodiments, hexamethylene diisocyanate (HDI) is used as the cross-linker, and the polyester prepolymer is provided in a ratio of between 3 to 1 and 20 to 1 (wt/wt) relative to HDI.
Table 1 relates the mechanical properties of elastomers of the present invention made with PGCL and HDI including young's modulus, ultimate tensile strength and elongation to break measured on INSTRON according to standard procedures (Dey, J. et al. (2008), Biomaterials 29: 4638-4649). Mechanical tests were carried out at room temperature in air or at 37° C. in water. The table shows the impact of varying the average molecular weight of the PGCL prepolymer from 20,000 g/mol to 100,000 g/mol, and varying the quantity of HDI provided relative to the PGCL. It is noted that the mechanical properties are determined by both the molecular weight of the prepolymer and also by the ratio of prepolymer:HDI used. Increasing molecular weight of the prepolymer results in more elastic materials. For a given molecular weight increasing the wt:wt ratio of HDI:polymer results in a stronger elastomer.
Table 2 relates mechanical properties of elastomers of the present invention made with PLCL and HDI. The PLCL/HDI elastomers behave similarly to the PGCL/HDI elastomers in that as molecular weight is increased from 8 k to 100 k the elongation to break increases. Additionally, for the lower molecular weight prepolymers, regardless of the ratio of prepolymer to isocyanate, the materials are stiff and have low elongation to break. Generally, PGCL based elastomers are stronger than PLCL based elastomers of similar molecular weight, and PGCL based elastomers have different degradation rates than PLCL based elastomers.
Table 3 sets forth the mechanical properties of polyester/urethane thermoset elastomers disclosed in the literature and measured on INSTRON according to standard procedures as discussed above. The thermoset elastomers listed in this table were prepared from a polyester prepolymer—poly(1,8-octanediol-co-citrate) (POC)—and then crosslinked with HDI. Although the elastomers of Table 3 are quite stiff, their elongation to break is far inferior to the elastomers of the present invention.
In addition to the molecular weight of the polyester prepolymer and ratio of prepolymer:isocyanate used, the choice of isocyanate cross-linker is also important in determining the final mechanical properties of the final elastomer. In a preferred embodiment, a symmetrical cross-linker is used, which has a plurality of isocyanate moieties of equal reactivity.
In certain embodiments, a catalyst may be used to catalyze the formation of the elastomer or a reaction involved therein, such as a gelling reaction. Any suitable catalyst may be used, including Zinc Octoate, Tin Octoate, Aluminum tris(acetylacetonate), etc. The type of catalyst used, or the absence of a catalyst, may influence the time and temperature required to fully cure the elastomer as shown in Table 4:
Surprisingly, the rate of degradation of elastomers of the invention (as measured by elastomer mass loss rate) is also affected by the presence or absence of a catalyst as shown in
The following examples illustrate aspects of the current invention in preferred embodiments without limitation of the spirit or scope of the claimed invention.
A 250 mL round-bottom flask was dried in oven at 110° C. and then cooled down to room temperature under a nitrogen atmosphere. Then, the flask was charged successively with Sn(Oct)2 (90 mg), pentaerythritol (400 mg), glycolide (60.0 g), and ε-caprolactone (60.0 g). Subsequently, the flask was equipped with a magnetic stirrer bar and a three-way valve connected to a nitrogen balloon. The flask was thoroughly degassed under reduced pressure and flushed with nitrogen. This process took 2-3 h. The flask was then placed into an oil bath (with 1000 mL silica oil) which was preheated to 185° C. The temperature of the oil bath quickly dropped to 155˜160° C. Meanwhile, the solid in the flask started to melt. Under vigorous stirring, the liquid in the flask became clear after 1˜2 min. Generally, the stirrer bar stopped within 5 min due to an increase in the viscosity of the liquid. The reaction was continued at 170° C. for another 22 h under a nitrogen atmosphere. After cooling to room temperature, the solid obtained was dissolved in ca. 300˜400 mL dichloromethane. The solution was filtered through a sintered glass funnel (pore size 70˜100 μm) to remove the insoluble particulate (e.g. polyglycolide) and then precipitated from 1000˜1200 mL anhydrous diethyl ether in a 1500 mL glass beaker. The solution was decanted and the residual sticky solid was washed with diethyl ether (150 mL×3). Subsequently, the beaker containing the materials was transferred to a vacuum oven operating at 55˜60° C. After 3 d, the fully dried polymer material was taken out and transferred to a polypropylene bottle for storage. Typically, around 110 g polymer could be recovered. A 1H NMR spectrum of the purified polymer in CDCl3 is shown in
A 4-arm PGCL (50:50) Mn 40000 g/mol (1.0 g) and hexamethylene diisocyanate (HDI) 125 μL were dissolved in 10 mL dichloromethane. The solution was placed in a aluminum pan with diameter of 9 cm. The solvent was evaporated at room temperature (ca. 20° C.) for 3 h. The residual film was cured in a 100° C. oven for 16 h.
Films were prepared in a similar manner to that outlined in Example 2 using a prepolymer PLCL (50:50) Mn of 56000 g/mol and either an asymmetric isocyanate, lysine diisocyanate (LDI), or a symmetrical one, (HDI, as crosslinking agent. The films were cured in the presence of 0.1% zinc octoate at 60° C. for 20 hrs. Table 4 shows resulting mechanical properties of films prepared from PLCL 50:50 prepolymer using several varying ratios of LDI and HDI. The ratio of isocyanate to prepolymer (NCO:OH) was optimized to maximize the mechanical properties.
To illustrate how differences in tear strength affects elastomer performance in coatings, solutions of polyester PLCL prepolymer and an optimized ratio of crosslinker (HDI or LDI) were prepared in dichloromethane, spray coated onto a braided PLGA 75:25 stent structure and cured to form a conformal elastomeric coating. The PLGA stent structure has dimensions of 7 mm outer diameter and a length of 20 mm pre coating. Coated stents were then crimped to a diameter of 1.85 mm using a MSI radial force tester and then allowed to recover their original diameter. SEM images of the stent structure are then taken.
The superior mechanical properties obtained from the HDI cured elastomer are due at least in part to the symmetrical nature of the crosslinker which symmetry allows it to crosslink in a homogenous manner when compared to LDI.
While various aspects and embodiments of the present invention have been described above, it should be understood that they have been presented by way of illustration rather than limitation. The breadth and scope of the present invention is intended to cover all modifications and variations that come within the scope of the following claims and their equivalents.
This application is a continuation-in-part of, and claims the benefit of priority to, U.S. patent application Ser. No. 12/783,261, filed May 19, 2010, now U.S. Pat. No. 8,137,396 by inventors Lee Core et al., entitled “Medical Implant,” and further claims the benefit of priority to U.S. Patent Application 61/179,834, filed May 20, 2009, by inventors Lee Core et al., entitled “Medical Implant,” to U.S. Patent Application 61/227,308, filed Jul. 21, 2009, by inventors Lee Core et al., entitled “Medical Implant,” and to U.S. Patent Application 61/251,984, filed Oct. 15, 2009, by inventors Lee Core et al.
Number | Name | Date | Kind |
---|---|---|---|
2957831 | Parker | Oct 1960 | A |
3150114 | Rockoff | Sep 1964 | A |
4243775 | Rosensaft et al. | Jan 1981 | A |
4300565 | Rosensaft et al. | Nov 1981 | A |
4461298 | Shalaby et al. | Jul 1984 | A |
4643734 | Lin | Feb 1987 | A |
4804691 | English et al. | Feb 1989 | A |
4916193 | Tang et al. | Apr 1990 | A |
4920203 | Tang et al. | Apr 1990 | A |
4990158 | Kaplan et al. | Feb 1991 | A |
5066772 | Tang et al. | Nov 1991 | A |
5145945 | Tang et al. | Sep 1992 | A |
5185408 | Tang et al. | Feb 1993 | A |
5213580 | Slepian et al. | May 1993 | A |
5256764 | Tang et al. | Oct 1993 | A |
5274074 | Tang et al. | Dec 1993 | A |
5356423 | Tihon | Oct 1994 | A |
5412068 | Tang et al. | May 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5468253 | Bezwada et al. | Nov 1995 | A |
5486593 | Tang et al. | Jan 1996 | A |
5516781 | Morris | May 1996 | A |
5531735 | Thompson | Jul 1996 | A |
5562725 | Schmitt | Oct 1996 | A |
5563146 | Morris | Oct 1996 | A |
5578662 | Bennett et al. | Nov 1996 | A |
5595751 | Bezwada et al. | Jan 1997 | A |
5616608 | Kinsella | Apr 1997 | A |
5634946 | Slepian | Jun 1997 | A |
5650447 | Keefer | Jul 1997 | A |
5665077 | Rosen | Sep 1997 | A |
5665728 | Morris | Sep 1997 | A |
5676963 | Keefer | Oct 1997 | A |
5703200 | Bezwada | Dec 1997 | A |
5716981 | Hunter | Feb 1998 | A |
5733925 | Kunz | Mar 1998 | A |
5741325 | Chaikof | Apr 1998 | A |
5762625 | Igaki | Jun 1998 | A |
5766710 | Turnlund | Jun 1998 | A |
5788979 | Alt et al. | Aug 1998 | A |
5797877 | Hamilton et al. | Aug 1998 | A |
5799384 | Schwartz et al. | Sep 1998 | A |
5824053 | Khosravi | Oct 1998 | A |
5834582 | Sinclair | Nov 1998 | A |
5851217 | Wolff | Dec 1998 | A |
5871535 | Wolff | Feb 1999 | A |
5899935 | Ding | May 1999 | A |
5968091 | Pinchuk et al. | Oct 1999 | A |
5984957 | Laptewicz | Nov 1999 | A |
5993972 | Reich et al. | Nov 1999 | A |
5994444 | Trescony | Nov 1999 | A |
5997468 | Wolff et al. | Dec 1999 | A |
6004346 | Wolff et al. | Dec 1999 | A |
6004573 | Rathi et al. | Dec 1999 | A |
6005020 | Loomis | Dec 1999 | A |
6051021 | Frid | Apr 2000 | A |
6074659 | Kunz | Jun 2000 | A |
6074660 | Jamiolkowski et al. | Jun 2000 | A |
6083257 | Taylor | Jul 2000 | A |
6083524 | Sawhney et al. | Jul 2000 | A |
6087479 | Stamler | Jul 2000 | A |
6117949 | Rathi et al. | Sep 2000 | A |
6120536 | Ding | Sep 2000 | A |
6153252 | Hossainy et al. | Nov 2000 | A |
6161399 | Jayaraman | Dec 2000 | A |
6171232 | Papandreou | Jan 2001 | B1 |
6171609 | Kunz | Jan 2001 | B1 |
6179051 | Ayub | Jan 2001 | B1 |
6193746 | Strecker | Feb 2001 | B1 |
6221100 | Strecker | Apr 2001 | B1 |
6221997 | Woodhouse et al. | Apr 2001 | B1 |
6232434 | Stamler | May 2001 | B1 |
6238687 | Mao et al. | May 2001 | B1 |
6240978 | Gianotti | Jun 2001 | B1 |
6245103 | Stinson | Jun 2001 | B1 |
6249952 | Ding | Jun 2001 | B1 |
6261594 | Smith | Jul 2001 | B1 |
6268390 | Kunz | Jul 2001 | B1 |
6270779 | Fitzhugh | Aug 2001 | B1 |
6284305 | Ding | Sep 2001 | B1 |
6290722 | Wang | Sep 2001 | B1 |
6295714 | Roychowdhury | Oct 2001 | B1 |
6299604 | Ragheb | Oct 2001 | B1 |
6299636 | Schmitt | Oct 2001 | B1 |
6306421 | Kunz | Oct 2001 | B1 |
6315791 | Gingras et al. | Nov 2001 | B1 |
6338739 | Datta | Jan 2002 | B1 |
6342068 | Thompson | Jan 2002 | B1 |
6368346 | Jadhav | Apr 2002 | B1 |
6379691 | Tedeschi | Apr 2002 | B1 |
6403635 | Kinsella | Jun 2002 | B1 |
6403759 | Stamler | Jun 2002 | B2 |
6419694 | Sandock | Jul 2002 | B1 |
6423092 | Datta | Jul 2002 | B2 |
6429232 | Kinsella | Aug 2002 | B1 |
6451337 | Smith | Sep 2002 | B1 |
6471978 | Stamler | Oct 2002 | B1 |
6488701 | Nolting et al. | Dec 2002 | B1 |
6488705 | Schmitt | Dec 2002 | B2 |
6488951 | Toone | Dec 2002 | B2 |
6500203 | Thompson et al. | Dec 2002 | B1 |
6506411 | Hunter | Jan 2003 | B2 |
6514515 | Williams | Feb 2003 | B1 |
6515009 | Kunz | Feb 2003 | B1 |
6537312 | Datta et al. | Mar 2003 | B2 |
6544544 | Hunter | Apr 2003 | B2 |
6569191 | Hogan | May 2003 | B1 |
6569195 | Yang | May 2003 | B2 |
6585764 | Wright | Jul 2003 | B2 |
6589546 | Kamath | Jul 2003 | B2 |
6592617 | Thompson | Jul 2003 | B2 |
6599928 | Kunz | Jul 2003 | B2 |
6605115 | Cooke | Aug 2003 | B1 |
6632242 | Igaki | Oct 2003 | B2 |
6632446 | Hubbell et al. | Oct 2003 | B1 |
6645518 | Tedeschi | Nov 2003 | B2 |
6656506 | Wu et al. | Dec 2003 | B1 |
6656966 | Garvey | Dec 2003 | B2 |
6663881 | Kunz | Dec 2003 | B2 |
6706274 | Herrmann | Mar 2004 | B2 |
6719934 | Stinson | Apr 2004 | B2 |
6730064 | Ragheb | May 2004 | B2 |
6737447 | Smith | May 2004 | B1 |
6743462 | Pacetti | Jun 2004 | B1 |
6753454 | Smith | Jun 2004 | B1 |
6776796 | Falotico | Aug 2004 | B2 |
6790228 | Hossainy | Sep 2004 | B2 |
6805898 | Wu et al. | Oct 2004 | B1 |
6808536 | Wright | Oct 2004 | B2 |
6855366 | Smith | Feb 2005 | B2 |
6869973 | Garvey | Mar 2005 | B2 |
6875840 | Stamler | Apr 2005 | B2 |
6884429 | Koziak | Apr 2005 | B2 |
6887266 | Williams et al. | May 2005 | B2 |
6887485 | Fitzhugh | May 2005 | B2 |
6908622 | Barry | Jun 2005 | B2 |
6932930 | DeSimone et al. | Aug 2005 | B2 |
6949112 | Sridharan et al. | Sep 2005 | B1 |
6974475 | Wall | Dec 2005 | B1 |
6991647 | Jadhav | Jan 2006 | B2 |
6997948 | Stinson | Feb 2006 | B2 |
7005137 | Hossainy et al. | Feb 2006 | B1 |
7008397 | Tweden | Mar 2006 | B2 |
7011678 | Tenerz | Mar 2006 | B2 |
7029495 | Stinson | Apr 2006 | B2 |
7063884 | Hossainy et al. | Jun 2006 | B2 |
7070615 | Igaki | Jul 2006 | B1 |
7087709 | Stamler | Aug 2006 | B2 |
7101566 | Rosenblatt et al. | Sep 2006 | B2 |
7141061 | Williams et al. | Nov 2006 | B2 |
7160323 | Pulnev et al. | Jan 2007 | B2 |
7160592 | Rypacek et al. | Jan 2007 | B2 |
7163554 | Williams et al. | Jan 2007 | B2 |
7163562 | Datta et al. | Jan 2007 | B2 |
7166133 | Evans et al. | Jan 2007 | B2 |
7217286 | Falotico | May 2007 | B2 |
7220816 | Pacetti et al. | May 2007 | B2 |
7223286 | Wright | May 2007 | B2 |
7229473 | Falotico | Jun 2007 | B2 |
7252679 | Fischell et al. | Aug 2007 | B2 |
7279005 | Stinson | Oct 2007 | B2 |
7279175 | Chen | Oct 2007 | B2 |
7285287 | Williams et al. | Oct 2007 | B2 |
7291165 | Rosenthal | Nov 2007 | B2 |
7292885 | Scott | Nov 2007 | B2 |
7300662 | Falotico | Nov 2007 | B2 |
7318945 | Thornton | Jan 2008 | B2 |
7348319 | Hrabie | Mar 2008 | B2 |
7348364 | Shalaby | Mar 2008 | B2 |
7361726 | Pacetti et al. | Apr 2008 | B2 |
7378106 | Hossainy | May 2008 | B2 |
7387641 | Schmitt | Jun 2008 | B2 |
7390333 | Dutta | Jun 2008 | B2 |
7416559 | Shalaby | Aug 2008 | B2 |
7419502 | Pulnev et al. | Sep 2008 | B2 |
7419503 | Pulnev et al. | Sep 2008 | B2 |
7419504 | Hossainy | Sep 2008 | B2 |
7425218 | Keefler | Sep 2008 | B2 |
7438712 | Chouinard | Oct 2008 | B2 |
7445628 | Ragheb | Nov 2008 | B2 |
7470283 | Dutta et al. | Dec 2008 | B2 |
7488444 | Furst et al. | Feb 2009 | B2 |
7491233 | Ding | Feb 2009 | B1 |
7491234 | Palasis et al. | Feb 2009 | B2 |
7498385 | Swetlin et al. | Mar 2009 | B2 |
7504125 | Pacetti et al. | Mar 2009 | B1 |
7517338 | Freyman et al. | Apr 2009 | B2 |
RE40816 | Taylor et al. | Jun 2009 | E |
7556842 | Worsham et al. | Jul 2009 | B2 |
7563483 | Hossainy et al. | Jul 2009 | B2 |
7585516 | Pacetti | Sep 2009 | B2 |
7594928 | Headley, Jr. et al. | Sep 2009 | B2 |
7604699 | Chen et al. | Oct 2009 | B2 |
7611533 | Bates et al. | Nov 2009 | B2 |
7618448 | Schmitz | Nov 2009 | B2 |
7648725 | Van Sciver et al. | Jan 2010 | B2 |
7658880 | Wu | Feb 2010 | B2 |
7682647 | Hossainy et al. | Mar 2010 | B2 |
7682648 | Ding et al. | Mar 2010 | B1 |
7718213 | Scheer | May 2010 | B1 |
7731740 | Lafont et al. | Jun 2010 | B2 |
7736386 | Pulnev et al. | Jun 2010 | B2 |
7758908 | Pham et al. | Jul 2010 | B2 |
7761968 | Huang et al. | Jul 2010 | B2 |
7763068 | Pulney et al. | Jul 2010 | B2 |
7763308 | Chen et al. | Jul 2010 | B2 |
7776381 | Tang et al. | Aug 2010 | B1 |
7776382 | Chappa et al. | Aug 2010 | B2 |
7794495 | Gale et al. | Sep 2010 | B2 |
7794776 | Limon et al. | Sep 2010 | B1 |
7794777 | Kokish et al. | Sep 2010 | B2 |
7833261 | Chen et al. | Nov 2010 | B2 |
7857844 | Norton et al. | Dec 2010 | B2 |
7875233 | Huang et al. | Jan 2011 | B2 |
7875283 | Hossainy et al. | Jan 2011 | B2 |
7879953 | Pacetti | Feb 2011 | B2 |
7901452 | Gale et al. | Mar 2011 | B2 |
7919162 | DeSimone et al. | Apr 2011 | B2 |
7923022 | Wang et al. | Apr 2011 | B2 |
7951185 | Abbate et al. | May 2011 | B1 |
7971333 | Gale et al. | Jul 2011 | B2 |
7972616 | Debrow et al. | Jul 2011 | B2 |
7985441 | Tang et al. | Jul 2011 | B1 |
8003156 | Van Sciver | Aug 2011 | B2 |
8016879 | Gale et al. | Sep 2011 | B2 |
8043553 | Durcan | Oct 2011 | B1 |
8058470 | Uyama et al. | Nov 2011 | B2 |
8137396 | Busold et al. | Mar 2012 | B2 |
20040044405 | Wolff | Mar 2004 | A1 |
20040106987 | Palasis | Jun 2004 | A1 |
20040181277 | Furst | Sep 2004 | A1 |
20040260272 | Friedman et al. | Dec 2004 | A1 |
20050142315 | DeSimone et al. | Jun 2005 | A1 |
20050214343 | Tremble | Sep 2005 | A1 |
20050214344 | Barrows et al. | Sep 2005 | A1 |
20060002977 | Dugan | Jan 2006 | A1 |
20060100568 | Tan | May 2006 | A1 |
20060121087 | Williams et al. | Jun 2006 | A1 |
20060147492 | Hunter et al. | Jul 2006 | A1 |
20060195059 | Freyman et al. | Aug 2006 | A1 |
20060204738 | Dubrow et al. | Sep 2006 | A1 |
20060246108 | Pacetti et al. | Nov 2006 | A1 |
20070026132 | Williams et al. | Feb 2007 | A1 |
20070038284 | Williams et al. | Feb 2007 | A1 |
20070093889 | Wu et al. | Apr 2007 | A1 |
20070110787 | Hossainy et al. | May 2007 | A1 |
20070123539 | Wu | May 2007 | A1 |
20070255422 | Wei et al. | Nov 2007 | A1 |
20070271763 | Huang et al. | Nov 2007 | A1 |
20070280851 | Freeman et al. | Dec 2007 | A1 |
20070281250 | Aono | Dec 2007 | A1 |
20070282247 | Desai et al. | Dec 2007 | A1 |
20070283552 | Gale et al. | Dec 2007 | A1 |
20070299504 | Gale et al. | Dec 2007 | A1 |
20080008739 | Hossainy et al. | Jan 2008 | A1 |
20080091262 | Gale et al. | Apr 2008 | A1 |
20080145393 | Trollsas et al. | Jun 2008 | A1 |
20080147161 | Chen et al. | Jun 2008 | A1 |
20080147164 | Gale et al. | Jun 2008 | A1 |
20080177375 | Chen et al. | Jul 2008 | A1 |
20080255267 | Domb et al. | Oct 2008 | A1 |
20080275539 | Williams et al. | Nov 2008 | A1 |
20080300669 | Hossainy | Dec 2008 | A1 |
20080306592 | Wang | Dec 2008 | A1 |
20090005860 | Gale et al. | Jan 2009 | A1 |
20090018643 | Hashi et al. | Jan 2009 | A1 |
20090062904 | Furst | Mar 2009 | A1 |
20090099600 | Moore et al. | Apr 2009 | A1 |
20090138076 | Palasis et al. | May 2009 | A1 |
20090216104 | DeSimone et al. | Aug 2009 | A1 |
20090285974 | Kerrigan et al. | Nov 2009 | A1 |
20090286761 | Cheng et al. | Nov 2009 | A1 |
20090304769 | Kunkel et al. | Dec 2009 | A1 |
20100198344 | Omura et al. | Aug 2010 | A1 |
20100298952 | Busold et al. | Nov 2010 | A1 |
20110238162 | Busold et al. | Sep 2011 | A1 |
20110319987 | Palasis et al. | Dec 2011 | A1 |
Number | Date | Country |
---|---|---|
1308473 | May 2003 | EP |
724436 | Jan 2004 | EP |
1382628 | Jan 2004 | EP |
1400218 | Apr 2004 | EP |
1700872 | Sep 2006 | EP |
2475778 | Jun 2011 | GB |
2003-246851 | May 2003 | JP |
9934750 | Jul 1999 | WO |
WO 2008029527 | Mar 2008 | WO |
2008076383 | Jun 2008 | WO |
2009158290 | Dec 2009 | WO |
Entry |
---|
Bhowmick, A.K.; Current Topics in Elastomer Research, 2008, p. 228-230. |
IUPAC Compendium of Chemical Terminology, Definition of Elastomer, 2014. |
Hietala et al., Thrombosis and Haemostatis, “Platelet deposition on stainless steel, spiral, and braided polylactide stents”, 92(6):1394-1401, (2004). |
International Search Report dated Jul. 21, 2010 for International Patent Application No. PCT/US2010/035417, (2pgs). |
G.A. Abraham, A. Marcos-Fernandez, J.S. Roman, Bioresorbable poly(ester-ether urethanes) from L-lysine diisocyanate and triblock copolymers with differenent hydrophilic character, J. Biomed. Mater. Res. A 2006 76, 729-736. |
P. Bruin, J. Smedinga, A. J. Pennings, M.F. Jonkman, Biodegradable lysine diisocyanate-based poly(glycolide-co-ε-caprolactone)-urethane network in artificial skin, Biomaterials 1990, 11, 291-295. |
A. O. Helminen, H. Korhonen, J. V. Seppala, Cross-linked poly(ε-caprolactone/D,L-lactide) copolymers with elastic properties, Macromol. Chem. Phys. 2002, 203, 2630-2639. |
L. Pinchuck, et al. (2008) Medical applications of poly(styrene-block-isobutyelene-blockstyrene) (“SIBS”), Biomaterials, 29, 448-460. |
J.E. Puskas, et al. (2004) Biomedical application of commercial polymers and novel polyisobutylene-based thermoplastic elastomers for soft tissue replacement, Biomacromolecules, 5, 1141-1154. |
J.E. Puskas, et al. (2009) Drug-eluting stent coatings, Wiley Interdiscip, Rev. Nanomed, Nanobiotechnol., 1, 451-462. |
Examination Report dated Jan. 21, 2011, issued in GB Application No. GB1008366.5. |
Search and Examination Report dated Sep. 1, 2010 issued in GB Application No. GB1008366.5. |
Examination Report dated May 5, 2011, issued in GB Application No. GB1008366.5. |
Examination Report dated Jul. 27, 2012 in European Patent Application No. GB1019777.0. |
Examination Report dated Feb. 6, 2013 in United Kingdom Patent Application No. GB1222543.9. |
Number | Date | Country | |
---|---|---|---|
20120142884 A1 | Jun 2012 | US |
Number | Date | Country | |
---|---|---|---|
61179834 | May 2009 | US | |
61227308 | Jul 2009 | US | |
61251984 | Oct 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12783261 | May 2010 | US |
Child | 13253720 | US |